Identification of c.683_684insCTGCAAGGACAAATCTGACGA pathogenic variant of the low-density lipoprotein receptor gene in a patient with familial hypercholesterolemia: a case report-Reference-Cited by-同舟云学术

Identification of c.683_684insCTGCAAGGACAAATCTGACGA pathogenic variant of the low-density lipoprotein receptor gene in a patient with familial hypercholesterolemia: a case report

Published:2023-09-05 Issue:7 Volume:22 Page:3581
ISSN:2619-0125
Container-title:Cardiovascular Therapy and Prevention
language:
Short-container-title:Cardiovasc Ther Prev

Author:

Korneva V. A.¹^ORCID,Mandelshtam M. Yu.²^ORCID,Orlov A. V.³^ORCID,Vasiliev V. B.²^ORCID,Kuznetsova T. Yu.¹^ORCID,Zakharova F. M.²^ORCID

Affiliation:

1. Petrozavodsk State University

2. Institute of Experimental Medicine

3. Institute of Biomedical Problems

Abstract

Familial hypercholesterolemia (FH) is one of the most common monogenic diseases that leads to the early development of atherosclerosis and is characterized by a poor prognosis. However, only about 1% of FH cases are diagnosed in Russia. The aim of this study was to determine the genetic defect in the FH family and conduct DNA diagnostics in the proband relatives. The study was performed on blood samples obtained with the informed consent of the patients. Polymerase chain reaction and polyacrylamide gel electrophoresis were used. We report c.683_684insCTGCAAGGA CAAATCTGACGA pathogenic variant of the low-density lipoprotein receptor (LDLR) gene for the first time in Russia and demonstrate its cosegregation in a family with high blood cholesterol. The c.683_684in sCTGCAAGGACAAATCTGACGA insertion is considered as a probable cause of FH.

Publisher

Silicea - Poligraf, LLC

Subject

Cardiology and Cardiovascular Medicine,Education

Reference14 articles.

1. Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, Aguilar-Salinas C, et al. Reducing the clinical and public health burden of familial hypercholesterolemia. A global call to action. JAMA Cardiol. 2020;5(2):217-29. doi:10.1001/jamacardio.2019.5173.

2. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi:10.1093/eurheartj/eht273.

3. EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a crosssectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713-25. doi:10.1016/S0140-6736(21)01122-3.

4. Zakharova FM, Golubkov VI, Lipovetsky BM, et al. Diagnostics of familial hypercholesterolemia in children from families with compromised inheritance. Voprosy sovremennoj pediatrii (Current Pediatrics). 2005;4(1):15-8. (In Russ.)

5. Sadykova DI, Galimova LF. Familial hypercholesterolemia in children: clinical manifestations, diagnosis, treatment. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2017;62(5):119-23. (In Russ.) doi:10.21508/1027-4065-2017-62-5-119-123.